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(LAM)It is well established that the rare progressive disease
lymphangioleiomyomatosis (LAM) occurs predominantly in
females of child bearing age. In addition, the pathological
features of LAM are widely documented. Thus the disease is
characterised by the invasion and proliferation of smooth
muscle- like cells- LAM cells- that replace normal lung tissue
and are accompanied by cystic destruction of lung parenchyma,
and excessive formation of lymph vessels or lymphangiogenesis.
LAM can be sporadic – S-LAM or associated with tuberous
sclerosis (TSC-LAM) and LAM associated lesions can also be
found in the retroperitoneal area and in the kidney asnal pathways leading to the functional effects
C-ND license.angiomyolipomas (AMLs). Symptoms of pulmonary LAM are
manifest as increasing dyspnoea due to tissue destruction,
pneumothorax or chylous effusion, together with haemoptysis.
Recent opinion has characterised LAM as a slowly progressive
neoplastic disorder [1].
Themolecular abnormality which underlies LAM involves the
mutational inactivation of the tuberous sclerosis gene complex
TSC-1 (hamartin) and TSC-2 (tuberin) [2]. Since the function of
the TSC complex is to constitute a braking system on cell
behaviour, its dysfunction is responsible for the uncontrolled
cell proliferation and migration which, together with cystcharacteristic of LAM with sites of potential therapeutic
E d i t o r i a l / r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 3 – 44formation and lymphangiogenesis, constitute the pathophysio-
logy of LAM.
Knowledge of the lack of function of the TSC-2 complex led to
the observation that rapamycin and its derivatives could be
useful as a therapeutic intervention in LAM, [3] in that they
inhibit mTORC1which would dampen the uncontrolled cellular
proliferation. Indeed, clinical trials have demonstrated that
rapamycin/sirolimus slows the decline of lung function, reduces
chylous effusions and shrinks the size of AMLs [4]. Moreover,
over a two year period, sirolimus decreased the number of LAM
cells detected in the circulation of women with LAM [5]. How-
ever, not all patients respond sufﬁciently well to rapamycin, and
in those that do, side effects can be problematic, and when
therapy ceases, symptoms and signs re-emerge.
It is therefore clear that additional or alternative drugs are
needed for the effective treatment of LAM, and consideration of
the pathophysiology of LAM provides direction. The cystic
destruction of lung tissue is likely to be mediated via increased
levels of matrix metalloproteinases (MMPs) especially MMP-2, the
activity of which can be inhibited by doxycycline- a tetracycline-
like antibiotic- in TSC-2 null cells and human LAM [6] but not by
rapamycin [7]. Levels of MMPs are raised in the serum of patients
with LAM and are decreased in patients administered doxycy-
cline. [8,9]. Whether or not the improvement in lung function is
directly related to MMP blockade is not established.
The fact that disease progression resumes with cessation of
therapy with rapamycin has led to the consideration of statins as
adjuvant therapy. Statins can inhibit cell growth at multiple
points in the signal transduction pathway viz Akt, p42/44ERK, as
well as mTORC2-dependent activation of RhoA [10]. Moreover,
statins can inhibit MMP levels [11] however these effects are
statin speciﬁc, and not common to all members of this class of
drugs [12].
Lymphangiogenesis is a prominent feature of LAM and is
associated with increased disease severity. We have found that
lung tissue of patients with LAM lacks the alpha 3 and 5 chain of
the collagen IV molecule. We have named the NC-1 domain of
the latter lamstatin, and have reported that both the recombi-
nant protein and a 17 amino acid peptide – CP17 decreased
lymphatic endothelial cell proliferation, cord formation and
migration. Lamstatin administered to mice decreased the lym-
phatic dysplasia associated with a lung carcinoma xenograft [13].
Recently, evidence has emerged from animal models and
the use of human cell lines that oestrogen may play a role in
the pathophysiology of LAM and that its inhibition via the
targeting of the oestrogen receptor may provide additional
therapeutic efﬁcacy [14,15].
It is therefore becoming apparent that the most effective
strategy in patients with LAM may be a combination of
pharmacotherapeutic interventions, based upon what is
known of the pathophysiology and cellular and molecular
abnormalities which constitute this disease (Fig. 1).
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